A Parallel Randomized Controlled Evaluation of Clopidogre... | EligiMed

A Parallel Randomized Controlled Evaluation of Clopidogrel Plus Aspirin, With Factorial Evaluation of Irbesartan, for the Prevention of Vascular Events, in Patients With Atrial Fibrillation

CompletadoFase 3ClinicalTrials.gov

ID: NCT00249795Tipo: INTERVENTIONALInicio: 1 de jun de 2003Fin estimado: 1 de ago de 2009

Traducción no disponible, mostrando original

Resumen

The purpose of this study was to determine if Irbesartan compared to Placebo would reduce the risk of vascular events such as heart attack, stroke, non-cerebral thromboembolic event and death in patients with Atrial Fibrillation (AF) and with at least one major risk of vascular events.

Descripción detallada

ACTIVE I was one of the 3 separate but related trials of the ACTIVE program conducted in AF patients at risk of vascular events. Patients were enrolled first into one of the 2 parallel trials of the ACTIVE program evaluating Clopidogrel: * ACTIVE A comparing clopidogrel + acetylsalicylic acid (ASA) and ASA alone * ACTIVE W comparing clopidogrel + ASA and oral anticoagulant (OAC). Then those satisfying additional criteria related to blood pressure and angiotensin receptor blocking agents were re-randomized in the two ACTIVE I arms according to a separate randomization list.

Elegibilidad

Edad mínima: 18 YearsSexo: ALL

Criterios de inclusión

Should fulfill the eligibility criteria for ACTIVE A or ACTIVE W trial and:
have a systolic blood pressure of at least 110 mmHg
not already receiving an angiotensin receptor blocking agent, unless they are willing and able to be changed to another antihypertensive agent
no previous intolerance to angiotensin receptor blocking agents
no proven indication for angiotensin receptor blocking agents, unless an Angiotensin Converting Enzyme (ACE) inhibitor can be substituted

Criterios de exclusión

Patients will be excluded from ACTIVE study if any of the following are present:
requirement for clopidogrel (such as recent coronary stent procedure)
requirement for oral anticoagulant (such as prosthetic mechanical heart valve)
prior intolerance to acetylsalicyclic acid (ASA) or clopidogrel
documented peptic ulcer disease within the previous 6 months
prior intracerebral hemorrhage
significant thrombocytopenia (platelet count \<50 x 10(9)/L)
psychosocial reason making study participation impractical
geographic reason making study participation impractical
ongoing alcohol abuse
mitral stenosis
pregnant or nursing woman or woman of child bearing potential and not on effective birth control for at least one month prior to start of study or not willing to continue on birth control for duration of study
severe comorbid condition such that the patient is not expected to survive 6 months
patient currently receiving an investigational pharmacologic agent
requirement for chronic (\> 3 months) non-cyclooxygenase-2 (non-COX-2) inhibitor nonsteroidal anti-inflammatory drug (NSAID) therapy unless willing enrolled in ACTIVE A

Intervenciones

drug

Irbesartan

oral administration (tablets) once daily

drug

placebo

oral administration (tablets) once daily

Ubicaciones

Sanofi-Aventis Administrative Office

Buenos Aires, Argentina

Patrocinadores

PrincipalSanofi

ColaboradorBristol-Myers Squibb

Aviso: La información de este ensayo proviene de fuentes públicas y tiene carácter exclusivamente informativo. No constituye asesoramiento médico, regulatorio ni de ningún otro tipo. Las traducciones son automatizadas y no poseen validez oficial. Consultá siempre con un profesional de la salud. Ver Términos de Uso.